Mobile

A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016800-22

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the effect of LY500307 once daily for 24 weeks versus placebo treatment in improving the IPSS in men with LUTS and prostatic enlargement secondary to BPH.

Critère d'inclusion

  • benign prostatic hyperplasia

Liens